Spago Nanomedical

Spago Nanomedical is a Swedish clinical-stage life science company developing nanomedicine-based products for cancer treatment and imaging diagnostics. Its core programs are Tumorad, a radionuclide therapy platform, and SpagoPix, a contrast agent platform for MRI-based imaging, both built on patented functional nanoparticles designed to accumulate in tumors.

— Spago Nanomedical
%
Radionuclide therapy development50% Development of Tumorad and the 177Lu-SN201 candidate for cancer treatment.
Imaging diagnostics development35% SpagoPix contrast-agent development for improved MRI precision in cancer and endometriosis.
Nanoparticle platform technology15% Patented functional nanoparticle platform used across therapeutic and diagnostic programs.

Spago Nanomedical does not sell to a broad commercial customer base today; its primary counterparties are...

  • Pharmaceutical license partnersprimary

    Buy or license late-stage development rights and commercialize the programs after proof of concept.

  • Clinical trial participants and sitesprimary

    Provide patient enrollment and clinical execution for Tumorad and related studies.

  • Biotech and research collaboratorssecondary

    Support development, validation, and translational work around the nanoparticle platform.

  • Healthcare end userssecondary

    Patients and clinicians ultimately use the therapy and imaging products once commercialized.

The company is headquartered in Lund, Sweden and operates as a Swedish listed clinical-stage developer on Nasdaq First...

  • •Headquartered in Lund, Sweden
  • •Listed on Nasdaq First North Growth Market
  • •Clinical development and corporate functions are Sweden-based
  • •Future commercialization is intended to be international
  • •Partnering model reduces dependence on a single geography

Spago Nanomedical’s strategy is to advance its nanoparticle-based programs through clinical proof of concept under its...

01
Clinical proof of concept for Tumoradshort-term

Clinical validation is the key value-inflection point for a radiopharmaceutical asset.

02
Advance SpagoPix imaging diagnosticsmedium-term

A second program broadens the platform and creates another partnering opportunity.

03
Secure strategic licensing or partnership agreementsmedium-term

Commercial partners provide development capacity, regulatory reach, and market access.

The business is exposed to the typical risks of clinical-stage drug development: technical failure, trial delays,...

high

Clinical development risk

The company must demonstrate safety, biodistribution, and efficacy in human studies before partnering value is realized.

Scope
Tumorad and SpagoPix programs
Materiality
high
high

Financing risk

The company is pre-commercial and depends on external funding to sustain R&D and trials.

Scope
Corporate runway and development programs
Materiality
high
medium

Intellectual property risk

The platform depends on patents and other rights to protect future licensing value.

Scope
Nanoparticle platform and candidate assets
Materiality
high
medium

Partnering and commercialization risk

Future revenues depend on finding capable licensees or collaborators with global reach.

Scope
Out-licensing model
Materiality
high
Public grants
Affects reported revenue/other income timing
Deferred tax assets
Loss carryforwards may not appear as balance-sheet value
Financial asset impairment
Can create volatility in financial items

Aligos Therapeutics, Inc.

ALGS · Biological Products, (No Diagnostic Substances)

CalciMedica, Inc.

CALC · Pharmaceutical Preparations

Vistagen Therapeutics, Inc.

VTGN · Pharmaceutical Preparations

AVANOS MEDICAL, INC.

AVNS · Orthopedic, Prosthetic & Surgical Appliances & Supplies

agilon health, inc.

AGL · Services-Misc Health & Allied Services, NEC

PERRIGO Co plc

PRGO · Pharmaceutical Preparations

: 11/08/2026